Bisphosphonate-Related Osteonecrosis of the Jaws: a real Challenge for Dentists

1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115–1117.10.1016/S0278-2391(03)00720-1Search in Google Scholar

2. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral MaxillofacSurg 2004; 62: 527-534.10.1016/j.joms.2004.02.004Search in Google Scholar

3. Salvatore L. Ruggiero, Thomas B. Dodson, John Fantasia, Reginald Goodday, Tara Aghaloo, Bhoomi Mehrotra, Felice O’Ryan. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery, 2014;72:1938–1956.10.1016/j.joms.2014.04.031Search in Google Scholar

4. Hewitt C, Farah CS. Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review. J Oral Pathol Med 2007;36: 319-328.10.1111/j.1600-0714.2007.00540.xSearch in Google Scholar

5. Bagger YZ, Tanko LB, Alexandersen P, Ravn P, Christiansen C. Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 2003;33: 301-307.10.1016/S8756-3282(03)00112-1Search in Google Scholar

6. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CYC. Severely suppresed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-1301.10.1210/jc.2004-095215598694Search in Google Scholar

7. Tong CK, Ho ST, Wong SL. Osteonecrosis of the jaw after oral bisphosphonate for osteoporosis. Hong Kong Med J 2010;16:145-148.Search in Google Scholar

8. Lugassy G, Shaham R, Nemets A, Ben-Dor D, Nahlieli O. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am J Med, 2004;117: 440-441.10.1016/j.amjmed.2004.04.01515380503Search in Google Scholar

9. Olson KB, Hellie CM, Pienta KJ. Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid. Urology, 2005;66:658.10.1016/j.urology.2005.03.02816140106Search in Google Scholar

10. VanPoznak C. The phenomenon of osteonecrosis of the jaw in patients with metastatic breast cancer. Cancer Invest, 2006;24:110-112.10.1080/0735790050044965216467002Search in Google Scholar

11. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws. J Oral Maxillofac Surg, 2007;65:369-376.10.1016/j.joms.2006.11.00317307580Search in Google Scholar

12. Krueger CD, West PM, Sargent M, Lodolce AE, Pickard AS. Bisphosphonate-Induced Osteonecrosis of the Jaw. Ann Pharmacother 2007;41:276-284.10.1345/aph.1H521Search in Google Scholar

13. Khan AA, Sándor GKB, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, Hanley DA, Chaudry SR, Dempster DW, Glorieux FH, Neville AJ, Talwar RM, Clokie CM, Al Mardini M, Paul T, Khosla S, Josse RG, Sutherland S, Lam DK, Carmichael RP, Blanas N, Kendler D, Petak S, St-Marie LG, Brown J, Evans AW, Rios L, Compston JE; Canadian Association of Oral and Maxillofacial Surgeons. Canadian Consensus Practice Guidelines for Bisphosphonate Associated Osteonecrosis of the Jaw. J Rheumatol 2008;35:1391-1397.Search in Google Scholar

14. Yamashita J, McCauley LK. Antiresorptives and osteonecrosis of the jaw. J Evid Base Dent Pract 2012:S1:233-247.10.1016/S1532-3382(12)70046-5Search in Google Scholar

15. Hayata K, Weissbach L, Kawashima M, Rubah H, Shanbhag A. Bisphosphonates modulate RANKL and OPG expression in human osteoblasts. Harvard Orthop J, 2005. Available at http://www.orthojournalhms.org/volume7/pdfs/ms07.pdf.Search in Google Scholar

16. Ohe JY, Kwon YD, Lee HW. Bisphosphonates modulate the expression of OPG and M-CSF in hMSC-derived osteoblasts. Clin Oral Investig 2012;16:1153–1159.10.1007/s00784-011-0614-z21938481Search in Google Scholar

17. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-1061.10.1124/jpet.102.03529512183663Search in Google Scholar

18. Saia G, Blandamura S, Bettini G, Tronchet A, Totola A, Bedogni G, et al. Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction. J Oral Maxillofac Surg, 2010;68:797–804.10.1016/j.joms.2009.10.02620307765Search in Google Scholar

19. Conte Neto N, Spolidorio LC, Andrade CR, Bastos S, Guimarães A, Marcantonio Jr ME. Experimental development of bisphosphonate-related osteonecrosis of the jaws in rodents. Int J Exp Pathol, 2013;94:65–73.10.1111/iep.12007357587523317355Search in Google Scholar

20. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-Induced Exposed Bone (Osteonecrosis/Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention, and Treatment. J Oral Maxillofac Surg 2005;63:1567-1575.10.1016/j.joms.2005.07.01016243172Search in Google Scholar

21. Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW, Sedghizadeh PP. The role of microbial biofilms in osteonecrosis of the jaw associated with bisphosphonate therapy. Curr Osteoporos Rep 2010;8:40–48.10.1007/s11914-010-0008-120425090Search in Google Scholar

22. Kaplan I, Anavi K, Anavi Y, Calderon S, Schwartz-Arad D, Teicher S, Hirshberg A. The clinical spectrum of Actinomyces-associated lesions of the oral mucosa and jawbones: correlations with histomorphometric analysis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;108:738–746.10.1016/j.tripleo.2009.06.01919748292Search in Google Scholar

23. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clézardin P. Bisphosphonates inhibit angiogenesis in vitro and testosterona-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62:6538–6544.Search in Google Scholar

24. Cankaya M, Cizmeci Senel F, Kadioglu Duman M, Muci E, Dayisoylu EH, Balaban F. The effects of chronic zoledronate usage on the jaw and long bones evaluated using RANKL and osteoprotegerin levels in an animal model. Int J Oral Maxillofac Surg. 2013;42:1134-1139.10.1016/j.ijom.2013.02.00823522850Search in Google Scholar

25. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102:433-441.10.1016/j.tripleo.2006.06.00416997108Search in Google Scholar

26. Chung WO, Dommisch H, Yin L, Dale BA. Expression of defensins in gingiva and their role in periodontal health and disease. Curr Pharm Des. 2007; 13:3073–3083.10.2174/13816120778211043517979750Search in Google Scholar

27. Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniades K. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol, 2009;27:5356.10.1200/JCO.2009.21.958419805682Search in Google Scholar

28. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carrière P, Dansey R. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012; 23: 1341.10.1093/annonc/mdr43521986094Search in Google Scholar

29. Fehm T, Beck V, Banys M, Lipp HP, Hairass M, Reinert S, Solomayer EF, Wallwiener D, Krimmel M. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol, 2009;112:605.10.1016/j.ygyno.2008.11.02919136147Search in Google Scholar

30. Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaws and bisphosphonates [Letter]. N Engl J Med, 2005;353:399.Search in Google Scholar

31. Hoff AO, Toth BB, Altundag K, Guarneri V, Adamus A, Nooka AK, Sayegh GG, Johnson MM, Gagel RF, Hortobagyi GN: Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. ASCO Annual Meeting Proceedings (postmeeting edition). J ClinOncol.2006; 24:8528. Available from: http://meeting.jco.org/cgi/content/abstract/24/18_suppl/8528.10.1200/jco.2006.24.18_suppl.8528Search in Google Scholar

32. Badros A, Weikel D, Salama A, et al: Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol, 2006;24:945.10.1200/JCO.2005.04.246516484704Search in Google Scholar

33. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons, American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws—2009 update. J Oral Maxillofac Surg. 2009;67(5 Suppl):2–12.10.1016/j.joms.2009.01.00919371809Search in Google Scholar

34. Maahs MP, Azambuja AA, Campos MM, Salum FG, Cherubini K. Association between bisphosphonates and jaw osteonecrosis: a study in Wistar rats. Head Neck 2011;33:199–207.10.1002/hed.2142220848442Search in Google Scholar

35. Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg, 2009;67:61–70.10.1016/j.joms.2009.01.00719371816Search in Google Scholar

36. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc, 2005;136:1658–1668.10.14219/jada.archive.2005.0108Search in Google Scholar

37. Ji X, Pushalkar S, Li Y, Glickman R, Fleisher K, Saxena D. Antibiotic effects on bacterial profile in osteonecrosis of the jaw. Oral Dis, 2012;18:85–95.10.1111/j.1601-0825.2011.01848.xSearch in Google Scholar

38. Thumbigere-Math V, Sabino MC, Gopalakrishnan R, Huckabay S, Dudek AZ, Basu S, Hughes PJ, Michalowicz BS, Leach JW, Swenson KK, Swift JQ, Adkinson C, Basi DL. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg, 2009;67:1904–1913.10.1016/j.joms.2009.04.051Search in Google Scholar

39. Berti-Couto SA, Vasconcelos AC, Iglesias JE, Figueiredo MA, Salum FG, Cherubini K. Diabetes mellitus and corticotherapy as risk factors for alendronate-related osteonecrosis of the jaws: a study in Wistar rats. Head Neck, 2014;36:84–93.10.1002/hed.23260Search in Google Scholar

40. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg, 2003;61:1104-1107.10.1016/S0278-2391(03)00328-8Search in Google Scholar

41. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol, 2005;23:8580.10.1200/JCO.2005.02.867016314620Search in Google Scholar

42. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, Bamia C, Terpos E, Tsionos K, Bamias A. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid. Haematologica, 2006;91:968-971.Search in Google Scholar

43. Tosi P, Zamagni E, Cangini D. Bisphosphonates and osteonecrosis of the jaws: Incidence in a homogeneous series of patients with newly diagnosed multiple myeloma treated with zoledronic acid. American Society of Hematology Annual Meeting Abstracts. Blood, 2005;106:3461.10.1182/blood.V106.11.3461.3461Search in Google Scholar

44. Pozzi S, Marcheselli R, Sacchi S. Analysis of frequency and risk factors for developing bisphosphonate associated necrosis of the jaw. American Society of Hematology Annual Meeting Abstracts. Blood, 2005;106:5057.10.1182/blood.V106.11.5057.5057Search in Google Scholar

45. Zavras AI, Zhu S. Bisphosphonate are associated with increased risk for jaw surgery in medical claims data: Is it osteonecrosis? J Oral Maxillofac Surg, 2006;64:917-923.Search in Google Scholar

46. Marx RE. Oral & intravenous bisphosphonate-induced osteonecrsis of the jaws—history, etiology, prevention and treatment. Chicago: Quintessence Publishing; 2007.Search in Google Scholar

47. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int, 2008;19:733–759.10.1007/s00198-007-0540-818214569Search in Google Scholar

48. Ruggiero SL, Woo SB. Bisphosponate-related osteonecrosis of the jaws. Dent Clin North Am, 2008;52:111–128.10.1016/j.cden.2007.09.00218154867Search in Google Scholar

49. Rosenberg T, Ruggiero S. Osteonecrosis of the jaws associated with the use of bisphosphonates. J Oral Maxillofac Surg, 2003;61(Suppl. 1):60.10.1016/S0278-2391(03)00566-4Search in Google Scholar

50. Clarke B, Boyette J, Vural E, Suen J, Anaissie E, Stack B. Bisphosphonates and jaw osteonecrosis: the UAMS experience. Otolaryngol Head Neck Surg, 2007;136:396–400.10.1016/j.otohns.2006.11.00817321866Search in Google Scholar

51. Ruggiero S, Mehrotra B. Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management. Annu Rev Med, 2009;60:85–96.10.1146/annurev.med.60.063007.13435018928335Search in Google Scholar

52. Campisi G, Fedele S, Fusco V, Pizzo G, Di Fede O, Bedogni A. Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. Future Oncology, 2014;10(2):257–275.10.2217/fon.13.21124490612Search in Google Scholar

53. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg, 2007;65:415–423.10.1016/j.joms.2006.10.06117307586Search in Google Scholar